Gatifloxacin (Photos: bms)
Gatifloxacin, one of the most widely prescribed antibiotics in North America, is likely to increase the risk of abnormalities in life-threatening blood sugar levels, according to a large-scale study by real Canadian scientists. show.
The study found that gatifloxacin antibiotic, sold under the Tequin brand manufactured by Bristol-Myers Squibb, is associated with an increased risk of decreased blood sugar levels when compared with other antibiotics.
Dr David Juurlink, a researcher at the ICES in Toronto, said: "We found that people taking gatifloxacin were at risk for hospitalization because their blood sugar levels were four times lower than those of users. Other antibiotics, and people taking gatifloxacin have a 17-fold higher risk of blood sugar .
CONFIDENTIAL
